INTRODUCTION: The diagnosis and treatment of antibody-mediated rejection (AMR) after lung transplantation has recently gained recognition within the transplant community. Extracorporeal photopheresis (ECP), currently used to treat chronic lung allograft dysfunction, modulates various pathways of the immune system known to be involved in AMR. We hypothesize that adding ECP to established AMR treatments could prevent the rebound of donor-specific antibodies (DSA). OBJECTIVES: This study aimed to analyze the role of ECP as an add-on therapy to prevent the rebound of DSA. METHODS: Lung transplant recipients who received ECP as an add-on therapy for pulmonary AMR between January 2010 and January 2019 were included in this single-center retrospective analysis. Baseline demographics of the patients, as well as their immunological characteristics and long-term transplant outcomes, were analyzed. RESULTS: A total of 41 patients developed clinical AMR during the study period. Sixteen patients received ECP as an add-on therapy after first-line AMR treatment. Among the 16 patients, 2 (13%) had pretransplant DSA, both against human leukocyte antigen (HLA) class I (B38, B13, and C06). Fifteen patients (94%) developed de novo DSA (dnDSA), i.e., 10 (63%) against class I and 14 (88%) against class II. The median time to dnDSA after lung transplantation was 361 days (range 25-2,548). According to the most recent International Society of Heart and Lung Transplantation (ISHLT) consensus report, 2 (13%) patients had definite clinical AMR, 6 (38%) had probable AMR, and 7 (44%) had possible AMR. The median mean fluorescence intensity (MFI) of dnDSA at the time of clinical diagnosis was 4,220 (range 1,319-10,552) for anti-HLA class I and 10,953 (range 1,969-27,501) for anti-HLA class II antibodies. ECP was performed for a median of 14 cycles (range 1-64). MFI values of dnDSA against HLA classes I and II were significantly reduced over the treatment period (for anti-class I: 752; range 70-2,066; for anti-class II: 5,612; range 1,689-21,858). The 1-year survival rate was 55%. No adverse events related to ECP were reported in any of the patients. CONCLUSIONS: ECP is associated with a reduction of dnDSA in lung transplant recipients affected by AMR. Prospective studies are warranted to confirm the beneficial effects of ECP in the setting of AMR.
INTRODUCTION: The diagnosis and treatment of antibody-mediated rejection (AMR) after lung transplantation has recently gained recognition within the transplant community. Extracorporeal photopheresis (ECP), currently used to treat chronic lung allograft dysfunction, modulates various pathways of the immune system known to be involved in AMR. We hypothesize that adding ECP to established AMR treatments could prevent the rebound of donor-specific antibodies (DSA). OBJECTIVES: This study aimed to analyze the role of ECP as an add-on therapy to prevent the rebound of DSA. METHODS: Lung transplant recipients who received ECP as an add-on therapy for pulmonary AMR between January 2010 and January 2019 were included in this single-center retrospective analysis. Baseline demographics of the patients, as well as their immunological characteristics and long-term transplant outcomes, were analyzed. RESULTS: A total of 41 patients developed clinical AMR during the study period. Sixteen patients received ECP as an add-on therapy after first-line AMR treatment. Among the 16 patients, 2 (13%) had pretransplant DSA, both against human leukocyte antigen (HLA) class I (B38, B13, and C06). Fifteen patients (94%) developed de novo DSA (dnDSA), i.e., 10 (63%) against class I and 14 (88%) against class II. The median time to dnDSA after lung transplantation was 361 days (range 25-2,548). According to the most recent International Society of Heart and Lung Transplantation (ISHLT) consensus report, 2 (13%) patients had definite clinical AMR, 6 (38%) had probable AMR, and 7 (44%) had possible AMR. The median mean fluorescence intensity (MFI) of dnDSA at the time of clinical diagnosis was 4,220 (range 1,319-10,552) for anti-HLA class I and 10,953 (range 1,969-27,501) for anti-HLA class II antibodies. ECP was performed for a median of 14 cycles (range 1-64). MFI values of dnDSA against HLA classes I and II were significantly reduced over the treatment period (for anti-class I: 752; range 70-2,066; for anti-class II: 5,612; range 1,689-21,858). The 1-year survival rate was 55%. No adverse events related to ECP were reported in any of the patients. CONCLUSIONS: ECP is associated with a reduction of dnDSA in lung transplant recipients affected by AMR. Prospective studies are warranted to confirm the beneficial effects of ECP in the setting of AMR.
Authors: Alin L Girnita; Rene Duquesnoy; Samuel A Yousem; Aldo T Iacono; Timothy E Corcoran; Manuela Buzoianu; Bruce Johnson; Kathy J Spichty; James H Dauber; Gilbert Burckart; Bartley P Griffith; Kenneth R McCurry; Adriana Zeevi Journal: Am J Transplant Date: 2005-01 Impact factor: 8.086
Authors: Jennifer M DeVos; A Osama Gaber; Richard J Knight; Geoffrey A Land; Wadi N Suki; Lillian W Gaber; Samir J Patel Journal: Kidney Int Date: 2012-05-23 Impact factor: 10.612
Authors: Shahideh Safavi; Derek R Robinson; Simona Soresi; Martin Carby; John D Smith Journal: J Heart Lung Transplant Date: 2014-07-21 Impact factor: 10.247
Authors: Don Hayes; Nicholas DiPaola; Peter B Baker; Stephen Kirkby; Alistair B Phillips; Kathleen K Nicol Journal: Transpl Immunol Date: 2012-08-15 Impact factor: 1.708
Authors: Susan Stewart; Michael C Fishbein; Gregory I Snell; Gerald J Berry; Annette Boehler; Margaret M Burke; Alan Glanville; F Kate Gould; Cynthia Magro; Charles C Marboe; Keith D McNeil; Elaine F Reed; Nancy L Reinsmoen; John P Scott; Sean M Studer; Henry D Tazelaar; John L Wallwork; Glen Westall; Martin R Zamora; Adriana Zeevi; Samuel A Yousem Journal: J Heart Lung Transplant Date: 2007-12 Impact factor: 10.247
Authors: L G Hidalgo; P M Campbell; B Sis; G Einecke; M Mengel; J Chang; J Sellares; J Reeve; P F Halloran Journal: Am J Transplant Date: 2009-11 Impact factor: 8.086
Authors: Deborah J Levine; Allan R Glanville; Christina Aboyoun; John Belperio; Christian Benden; Gerald J Berry; Ramsey Hachem; Don Hayes; Desley Neil; Nancy L Reinsmoen; Laurie D Snyder; Stuart Sweet; Dolly Tyan; Geert Verleden; Glen Westall; Roger D Yusen; Martin Zamora; Adriana Zeevi Journal: J Heart Lung Transplant Date: 2016-02-10 Impact factor: 10.247
Authors: Jennifer Schneiderman; Longhui Qiu; Xin Yi Yeap; Xin Kang; Feibo Zheng; Junsheng Ye; Yan Xie; Jiao-Jing Wang; Yuvaraj Sambandam; James Mathew; Lin Li; Joseph Leventhal; Richard L Edelson; Zheng Jenny Zhang Journal: Sci Rep Date: 2022-05-04 Impact factor: 4.996